Serum PSA as a tumor marker for patients undergoing definitive radiation therapy.
This article summarizes the clinical utility of PSA both as pretreatment prognostic factor and as an invaluable post-treatment marker. Some pathobiologic correlations between serum PSA kinetics and putative tumor cell kinetic mechanisms are discussed.
Zagars
G K
GK
University of Texas, MD Anderson Cancer Center, Houston.
D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000532:radiotherapy*
D017430:Prostate-Specific Antigen